News

FDA panel unanimously backs cobas HPV test as primary screening tool


 

AT AN FDA ADVISORY COMMITTEE MEETING

The FDA usually follows the recommendations of its advisory panels.

Advisory panel members have been cleared of potential conflicts related to the meeting topic. Occasionally, a panelist is given a waiver, but no waivers were given at this meeting.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

No higher risk of cancer after 9 years of testosterone replacement therapy
MDedge Hematology and Oncology
ASCO guidelines for fertility preservation affirm oocyte preservation
MDedge Hematology and Oncology
No increased cancer risk in children born after assisted conception
MDedge Hematology and Oncology
Finasteride use in prevention not linked to higher mortality
MDedge Hematology and Oncology
Many women with cancer not told about impaired fertility risk
MDedge Hematology and Oncology
Hormone therapy’s protection against endometrial cancer persists in Women’s Health Initiative follow-up study
MDedge Hematology and Oncology
Exercise protects black women against ER-negative breast cancer
MDedge Hematology and Oncology
Older men with prostate cancer have greater risk of CVD, diabetes after prolonged hormonal therapy
MDedge Hematology and Oncology
Prophylactic oophorectomy cuts all-cause mortality 77% in BRCA mutation carriers
MDedge Hematology and Oncology
Hormone therapy predicted improved lung cancer survival in women
MDedge Hematology and Oncology